Immunopathology & Immunotherapy
10.4K views | +0 today
Follow
Immunopathology & Immunotherapy
Latest advances in immunopathology diagnosis and treatment
Curated by Alfredo Corell
Your new post is loading...
Your new post is loading...
Scooped by Alfredo Corell
Scoop.it!

Descubiertas unas ‘células escudo’ que protegen los tumores

Descubiertas unas ‘células escudo’ que protegen los tumores | Immunopathology & Immunotherapy | Scoop.it
Su desactivación facilita los tratamientos inmunológicos contra el cáncer
Alfredo Corell's insight:

La inmunoterapia contra el cáncer —enseñar al sistema de defensa del organismo a atacar a las células tumorales— se presenta como la nueva revolución en oncología. Pero no es fácil. La revista Nature Medicine ha publicado un artículo en el que el proceso no se centra directamente en combatir las células tumorales, sino en otras que pululan a su alrededor y que, de alguna manera, hacen de escudo.


artículo en Nature Medicine: http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3560.html

No comment yet.
Scooped by Alfredo Corell
Scoop.it!

The Vicious Cycle of Under-Valued Cancer Biomarkers

The Vicious Cycle of  Under-Valued Cancer Biomarkers | Immunopathology & Immunotherapy | Scoop.it
Larry H Bernstein, MD, FCAP, Reporter    Reblog Clinical Laboratory News Nov 2013;  39( 11)   The Vicious Cycle of  Under-Valued Cancer Biomarkers  Could Sweeping Changes Bring More Tests Into Clin...
Alfredo Corell's insight:
 Comment by reviewer:

The clinical laboratory has been concentrating on technical accuracy considerably beyond the clinical utility of many observations in clinical medicine.  This is not necessarily appreciated, so when a test is inconsistent with the clinical hypothesis, it may be rejected as error.  Errors may occur, but are rare, except if there is specimen misidentification.  However, we are still focused on a “silver bullet” approach to use of diagnostic tests.  There is some variability of the expression of cancer cells, so that there are subclusters to be expected within a major class.  The level of applied mathematics that is needed to analyze this data has been refined enormously in the last decade, and has to be used on the selected groups of tests referred to with all due respect by Leigh Anderson, who has the imagination to pursue the highest accuracy in large scale MS analysis that his laboratory has pursued for many years.  This reviewer is interested in the “information content” of a combination of tests, when the accuracy of testing is no longer an issue.  By combining the high throuput and lower cost of processing, with vastly better mathematical technology than is customary – on the fly – would be a breakthrough.  That would not be the end of this journey because there would have to be centers for analysis distributed within a few hours of the treatment centers (or at those sites), so that testing and processing would enable better facilitation of treatment.

No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Targeting Cancer with a Lupus Autoantibody - Sci Transl Med 24 October 2012

Targeting Cancer with a Lupus Autoantibody - Sci Transl Med 24 October 2012 | Immunopathology & Immunotherapy | Scoop.it

Sci Transl Med 24 October 2012:
Vol. 4, Issue 157, p. 157ra142
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3004385

 

CancerTargeting Cancer with a Lupus Autoantibody

this study provides the basis for the potential use of a lupus anti-DNA antibody in cancer therapy and identifies lupus autoantibodies as a potentially rich source of therapeutic agents.

 

James E. Hansen1,2,*,Grace Chan3,Yanfeng Liu1,Denise C. Hegan1,Shibani Dalal1,Eloise Dray4,†,Youngho Kwon4,Yuanyuan Xu4,Xiaohua Xu5,Elizabeth Peterson-Roth1,Erik Geiger1,Yilun Liu5,Joseph Gera3,6,Joann B. Sweasy1,2,7,8,Patrick Sung1,2,4,Sara Rockwell1,2,9,Robert N. Nishimura3,10,Richard H. Weisbart3 andPeter M. Glazer1,2,8,*

 

See also a summary in the news:

http://www.voanews.com/content/autoimmune-disease-antibodies-help-fight-cancer/1533596.html?goback=.gde_151241_member_179119923

 

 

No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Multivitamins in the Prevention of Cancer in Men - JAMA (The Journal of the American Medical Association) October 17, 2012

Multivitamins in the Prevention of Cancer in Men - JAMA (The Journal of the American Medical Association) October 17, 2012 | Immunopathology & Immunotherapy | Scoop.it

J. Michael Gaziano, MD, MPH; Howard D. Sesso, ScD, MPH; William G. Christen, ScD; Vadim Bubes, PhD; Joanne P. Smith, BA; Jean MacFadyen, BA; Miriam Schvartz, MD; JoAnn E. Manson, MD, DrPH; Robert J. Glynn, ScD; Julie E. Buring, ScD

JAMA. 2012;():1-10. doi:10.1001/jama.2012.14641.

Published online October 17, 2012

Conclusion In this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total cancer.

 

Comments on Medscape

http://www.medscape.com/viewarticle/772811?src=mpnews&spon=7

 

No comment yet.
Scooped by Alfredo Corell
Scoop.it!

What Is Cancer Immunotherapy?

What Is Cancer Immunotherapy? | Immunopathology & Immunotherapy | Scoop.it
Infographic about cancer immunotherapy and how the immune system can be harnessed to conquer many types of cancer.
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

New technique could make cell-based immune therapies for cancer safer and more effective

New technique could make cell-based immune therapies for cancer safer and more effective | Immunopathology & Immunotherapy | Scoop.it
Scientists have shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.
Alfredo Corell's insight:

Here you have the original publication in Nature Biotechnology:http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.2459.html

 

No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Aprobado un fármaco que quintuplica la supervivencia al melanoma metastásico

Aprobado un fármaco que quintuplica la supervivencia al melanoma metastásico | Immunopathology & Immunotherapy | Scoop.it

Aprobado un fármaco que quintuplica la supervivencia al melanoma metastásico

El Ministerio de Sanidad ha aprobado el uso y la financiación pública del ipilimumab, una novedosa inmunoterapia contra el melanoma metastásico. Según los ensayos del laboratorio que lo ha desarrollado, BMS, este fármaco prolonga la supervivencia de los afectados de una media de seis o nueve meses a hasta cinco años.

No comment yet.